Latest Conference Articles

In this preview of the 2023 Community Oncology Conference, past president of the Community Oncology Alliance, David Eagle, MD, of New York Cancer & Blood Specialists, discusses what has him excited for this year's meeting, both sessions and speakers.

Shiela Plasencia, director of practice support at the Community Oncology Alliance, shares what she's looking forward to at the 2023 Community Oncology Conference.

The 2023 American Academy of Dermatology Annual Meeting, held in New Orleans, Louisiana, from March 17-21, 2023, will feature research and presentations exploring the mechanisms, presentation, and treatment of dermatological disorders.

There is a lot to talk about in the vitiligo space at this year’s annual meeting of the American Academy of Dermatology (AAD), said John Harris, MD, PhD, FAAD, director of the Vitiligo Clinic and Research Center at UMass Chan Medical School.

Members of the Association of Community Cancer Centers (ACCC) Alternative Payment Coalition discussed strategies for succeeding in value-based care and voiced concerns surrounding the upcoming Enhancing Oncology Model (EOM) during a panel discussion at the ACCC 2023 Annual Meeting and Business Summit.

Jeff Hunnicutt, CEO of Highlands Oncology Group, explains the 2 risk options provided under the Enhancing Oncology Model (EOM) and why the mandatory downside risk might give pause to practices that saw some success in the Oncology Care Model.

As scientists are identifying molecular alterations in patients with later-stage cancers that may be targets in earlier-stage disease, next-generation sequencing is being utilized more in the first-line setting, noted Sigrun Hallmeyer, MD, medical oncologist with Advocate Health.

Kevin Davies, PhD, executive editor, The CRISPR Journal and GEN Biotechnology, discusses how CRISPR has evolved from the initial discovery of the double helix to now, with the technology holding great promise for both genetic diseases and cancers.

A session at the ACCC 2023 Annual Meeting and Cancer Center Business Summit addressed the promise and potential drawbacks of multicancer early detection (MCED) testing for patients in the primary care setting.

In the first keynote session at the ACCC 2023 Annual Meeting and Cancer Center Business Summit, the history of CRISPR genome editing and its potential in cancer and other settings took center stage.

Andre Harvin, PharmD, MS, MBA, Cone Health Cancer Center, discusses the vital role of pharmacists in oncology: how they use data to streamline patient visits, work to facilitate patient access to biosimilars, and advocate for their patients.

Ajai Chari, MD, professor of medicine and director of clinical research in the Multiple Myeloma Program at Mount Sinai in New York, discusses a post-hoc analysis of data from the phase 2 GRIFFIN trial.

Speaking at the 72nd American College of Cardiology Scientific Session in New Orleans on Sunday, Clyde W. Yancy, MD, MSc, the vice dean for diversity and inclusion at the Feinberg School of Medicine at Northwestern University, challenged the audience to rethink what success looks like in health care.

Results for the STELLAR trial, presented at the 72nd American College of Cardiology (ACC) Scientific Session Together With the World Congress of Cardiology, hit nearly every mark: patients taking sotatercept improved their performance on a 6-minute walk test by 40.8 meters, which was the primary end point, and achieved 8 of 9 secondary end points.

Olalekan Ajayi, PharmD, MBA, chief operating officer of Highlands Oncology Group, PA, and 2023-2024 president-elect of the Association of Community Cancer Centers (ACCC), discusses why he is excited for this year’s meeting, including its many workshops and day 1 keynote on CRISPR.

The Association of Community Cancer Centers (ACCC) 49th Annual Meeting and Cancer Center Business Summit will feature presentations and interactive workshops centered on the latest in technology, care delivery, and payment issues in oncology.

The findings of the ACCESS study show the complex challenge of improving medication adherence among the most fragile members of society.

Baxdrostat is a highly selective aldosterone synthase inhibitor; phase 1 studies showed that the therapy caused a sustained, dose-dependent reduction in plasma aldosterone by more than 70% without reducing cortisol.

Results from the CLEAR Outcomes trial were presented today at the 72nd American College of Cardiology (ACC) Scientific Session Together With the World Congress of Cardiology. Plans for a broader label are in the works.

Deepak L. Bhatt, MD, MPH, Icahn School of Medicine at Mount Sinai, has multiple presentations during the upcoming American College of Cardiology Scientific Sessions, including additional phase 2 results from the ENTRIGUE trial for pegozafermin in severe hypertriglyceridemia. 

The 72nd American College of Cardiology Scientific Session Together With the World Congress of Cardiology (ACC.23/WCC), runs from Saturday to Monday in New Orleans, Louisiana.

Braden Manns, MD, MSc, a nephrologist and health economics researcher at the University of Calgary in Canada, will present the results of a randomized trial evaluating the impact of removing co-payments for drugs that treat chronic conditions on cardiovascular outcomes during the American College of Cardiology Scientific Sessions in New Orleans, Louisiana, on Sunday, March 5.

Utilizing real-world evidence that applies to the specific care needs of certain patient populations can promote timely decision-making among payers and providers on the use of effective cancer therapies available on the market, said panelists at the 2022 Patient-Centered Oncology Care® (PCOC) meeting.

At Patient-Centered Oncology Care®, Debra Patt, MD, PhD, MBA, of Texas Oncology, discussed managed care considerations that arise from the groundbreaking DESTINY-Breast04 study presented earlier this year.

A panel of experts discussed the explosion of information and advances in cancer genomics and the accompanying challenges of understanding the data and taking action.

Guideline-directed cancer care—with help from a clinical support tool—can close disparities while reducing costs more efficiently than other means, such as prior authorization.

While the current therapies are effective for treating branch retinal vein occlusion (BRVO) and central retinal vein occlusion (CRVO), they are inadequate for long-term treatment in clinical practice, according to an analysis of real-world data.

Two studies looking at a higher dose of aflibercept found that an 8-mg dose can be maintained at longer dosing intervals with similar benefits and no additional safety signals compared with the 2-mg dose.

Much of the evidence that has been used to base current standard of care for diabetic eye diseases stems from studies performed by the DRCR Retina Network over the years.

The BUTTERFLEYE trial sought to determine if aflibercept, an anti–vascular endothelial growth factor (anti-VEGF) therapy, was equivalent to laser photocoagulation, the gold standard to treat retinopathy of prematurity (ROP) in preterm babies.